GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guangzhou Innogen Pharmaceutical Group Co 2591.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

3.68

+1.66%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥149.2m

FY2022FY2025

Net income

−CN¥387.3m

FY2022FY2025

Free cash flow

−CN¥369.8m

FY2022FY2025

Shareholders' equity

CN¥1.23bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
RevenueCN¥149.2m———
Gross profitCN¥121.6m−CN¥20.1m−CN¥22.9m−CN¥22.2m
Research and developmentCN¥226.3mCN¥119.4mCN¥573.1mCN¥317.1m
Operating income−CN¥388.9m−CN¥220.5m−CN¥869.8m−CN¥381.4m
Net income−CN¥387.3m−CN¥203.4m−CN¥854.1m−CN¥357.5m
Diluted earnings per share-0.88-0.45-1.87-0.78

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assetsCN¥1.83bnCN¥1.09bnCN¥1.29bnCN¥778.8m
Cash and short-term investmentsCN¥1.40bnCN¥928.1mCN¥1.10bnCN¥583.9m
Total liabilitiesCN¥603.1mCN¥161.1mCN¥466.1mCN¥157.5m
DebtCN¥193.7mCN¥9.9mCN¥46.6mCN¥6.3m
Shareholders' equityCN¥1.23bnCN¥927.6mCN¥821.2mCN¥621.3m
Shares outstanding442m457m457m457m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−CN¥344.2m−CN¥189.4m−CN¥191.7m−CN¥229.8m
Capital spending−CN¥25.7m−CN¥5.0m−CN¥14.2m−CN¥33.6m
Free cash flow−CN¥369.8m−CN¥194.4m−CN¥205.9m−CN¥263.4m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023
RevenueCN¥89.8mCN¥86.0mCN¥64.4m————
Gross profitCN¥57.4mCN¥76.2mCN¥57.6m−CN¥8.7m−CN¥11.3m−CN¥11.2m−CN¥11.9m
Operating income−CN¥135.6m−CN¥250.3m−CN¥132.3m−CN¥105.0m−CN¥96.3m−CN¥452.9m−CN¥426.3m
Net income−CN¥132.6m−CN¥250.7m−CN¥139.8m−CN¥118.0m−CN¥88.4m−CN¥444.8m−CN¥417.4m
Diluted earnings per share-0.29-0.57-0.32-0.26-0.19-0.97-0.91
Cash from operations−CN¥158.0m−CN¥242.0m−CN¥99.0m−CN¥98.0m−CN¥94.0m−CN¥108.0m−CN¥82.0m
Capital spending−CN¥2.0m−CN¥18.0m−CN¥4.0m−CN¥1.0m−CN¥3.0m−CN¥8.0m−CN¥5.0m
Free cash flow−CN¥160.0m−CN¥260.0m−CN¥103.0m−CN¥99.0m−CN¥97.0m−CN¥116.0m−CN¥87.0m
Total assetsCN¥1.51bnCN¥1.83bnCN¥1.09bnCN¥1.09bnCN¥1.14bnCN¥1.28bn—
Cash and short-term investmentsCN¥1.19bnCN¥1.40bnCN¥854.8mCN¥928.1mCN¥1.01bnCN¥1.10bn—
DebtCN¥161.9mCN¥193.7mCN¥63.4mCN¥11.5m—CN¥6.8m—
Shareholders' equityCN¥1.10bnCN¥1.23bnCN¥795.1mCN¥927.6mCN¥1.03bnCN¥818.8m—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income0.7%——
Net income2.7%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-30.1
Price to sales78.2

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.